Back

Microbiota-derived indole metabolites inhibit rotavirus infection in vitro and in vivo and in human infants

Wirusanti, N. I.; van Schajik, Y.; Kim, J.; Frempong, J. F.; Simkhada, N.; Fisher, S.; Pucci, N.; Piedade, G. J.; Luchen, C. C.; Chibuye, M.; Simuyandi, M.; Chisenga, C.; Silwamba, S.; Chibesa, K.; Nzangwa, B. T.; Kuntawala, D. H.; Ramani, S.; Mende, D.; Baldridge, M. T.; Sovran, B.; Harris, V. C.

2025-10-29 microbiology
10.1101/2025.10.29.685378 bioRxiv
Show abstract

Rotavirus (RV) is the leading cause of life-threatening gastroenteritis in children under five despite effective RV vaccines availability, necessitating novel protective strategies for high-risk populations. Gut microbiota can modulate RV susceptibility and vaccine immunogenicity, yet underlying mechanisms are poorly characterized. Here, we demonstrate that microbiota-derived indole metabolites confer protection against RV infection. In healthy adults, higher fecal indole-3-acetic acid (IAA) and indole-3-propionic acid (IPA) levels associated with reduced fecal RV shedding following challenge. In human intestinal enteroids (HIEs), IAA pre-treatment inhibited human RV Wa G1P[8] replication via the aryl hydrocarbon receptor (AhR) pathway. In mice, treatment with AhR agonist indole-3-carbinol (I3C) significantly reduced fecal shedding of murine RV strain EDIM-Cambridge. Finally, Zambian infants with active RV infection exhibited lower fecal IAA and IPA levels than age-matched healthy controls. These findings demonstrate that microbiota-derived AhR ligands consistently inhibit RV infection across three experimental models and hold promise for protecting at-risk pediatric populations.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.